You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
Colorcon
Express Scripts
Merck
Medtronic

Last Updated: July 15, 2020

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 079139

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

NDA 079139 describes LITHIUM CARBONATE, which is a drug marketed by Able, Alembic Ltd, Apotex Inc, Glenmark Generics, Hetero Labs Ltd Iii, Hikma, Mylan, Usl Pharma, Watson Labs, Alembic Pharms Ltd, Glenmark Pharms Inc, Heritage Pharma, Hikma Intl Pharms, Mylan Pharms Inc, Unique Pharm Labs, Pfizer, and Sun Pharm Inds Inc, and is included in twenty-nine NDAs. It is available from twenty-two suppliers. Additional details are available on the LITHIUM CARBONATE profile page.

The generic ingredient in LITHIUM CARBONATE is lithium carbonate. There are fifteen drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the lithium carbonate profile page.
Summary for 079139
Tradename:LITHIUM CARBONATE
Applicant:Glenmark Generics
Ingredient:lithium carbonate
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 079139
Medical Subject Heading (MeSH) Categories for 079139
Suppliers and Packaging for NDA: 079139
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
LITHIUM CARBONATE lithium carbonate CAPSULE;ORAL 079139 ANDA Glenmark Pharmaceuticals Inc., USA 68462-220 68462-220-01 100 CAPSULE in 1 BOTTLE (68462-220-01)
LITHIUM CARBONATE lithium carbonate CAPSULE;ORAL 079139 ANDA Glenmark Pharmaceuticals Inc., USA 68462-220 68462-220-11 10 BLISTER PACK in 1 BOX, UNIT-DOSE (68462-220-11) > 10 CAPSULE in 1 BLISTER PACK

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength150MG
Approval Date:Feb 3, 2009TE:ABRLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength300MG
Approval Date:Feb 3, 2009TE:ABRLD:No

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength600MG
Approval Date:Feb 3, 2009TE:ABRLD:No

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Boehringer Ingelheim
Johnson and Johnson
Baxter
McKinsey
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.